Agios
Agios Pharmaceuticals, often referred to simply as Agios, is a prominent biopharmaceutical company headquartered in the United States. Founded in 2008, Agios has established itself as a leader in the field of metabolic oncology, focusing on the discovery and development of innovative therapies for cancer and rare genetic diseases. With a strong emphasis on precision medicine, Agios has made significant strides in developing unique small molecule drugs that target specific metabolic pathways. Their flagship products, including therapies for acute myeloid leukaemia and hereditary cancer syndromes, highlight the company's commitment to addressing unmet medical needs. Recognised for its pioneering research and development efforts, Agios continues to solidify its market position through strategic partnerships and a robust pipeline of potential treatments, making it a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Agios's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Agios's score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Agios's reported carbon emissions
Agios, headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets outlined. Without emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). However, the absence of documented reduction initiatives or climate pledges suggests that Agios may still be in the early stages of formalising its climate commitments. As the industry increasingly prioritises sustainability, it will be essential for Agios to establish clear targets and strategies to address climate change and reduce its environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Agios is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
